Sep 2026· Iraqi Journal of Pharmaceutical Sciences· Vol 35, pp. 38-45· 0 citations· 27 references
TL;DR
Vitamin D3 deficiency significantly reduces the effectiveness of atorvastatin (ATO) in Iraqi patients with dyslipidemia, and there was a significant association between vitamin D3 deficiency and the efficacy of atorvastatin at P <0.05.
Abstract
Dyslipidemia is an abnormal elevation of lipid levels in the blood, which may involve cholesterol and triglycerides. The response of dyslipidemia to statin therapy is diverse, ranging from 5-70% and this may be related to vitamin D3 deficiency. A study aims to assess the effect of vitamin D3 deficiency on the therapeutic response to atorvastatin. The cohort study involved 243 dyslipidemic patients who received different doses of atorvastatin according to the 2018 American Heart Association/American College of Cardiology cholesterol guidelines. The serum lipid profile level, vitamin D3, and atherogenic index were measured. The serum level of Total cholesterol and low-density lipoprotein-cholesterol, and atherogenic index were significantly reduced, and the serum level of high-density lipoprotein-cholesterol was elevated considerably in the responded patients compared to the non-responded patients at P <0.05. The serum level of vitamin D3 was significantly low in the non-responded patients compared to respond patients at P <0.05. There was a significant association between vitamin D3 deficiency (95% CI 0.759 – 0.849) and a decrease in the efficacy of atorvastatin at P <0.05. In conclusion, Vitamin D3 deficiency significantly reduces the effectiveness of atorvastatin (ATO) in Iraqi patients with dyslipidemia.
As civilization progress, the number of older people is constantly growing. Furthermore, they suffer a higher burden of comorbidity and polipharmacy, which has a significant impact on the overall well-being of people in this age group. Elderly people are at risk of vitamin D deficiency, which is necessary for the prope...
Aldona Molęda, Marzena Majchrowska, Aleksandra Kuzan· Medycyna Pracy· 0 citations
Hypercholesterolemia is characterized by increased levels of LDL, total cholesterol, triglycerides, and decreased levels of HDL, caused by various variables, one of which is age. With age, a person's ability to bind to the LDL receptor decreases. This results in an increase in the amount of LDL present in the blood whi...
Shella Amanda, S. Rahmat· International Journal of Hea...· 0 citations
Introduction: Roux-en-Y gastric bypass demonstrates high efficacy in reversing vitamin D deficiency and improving the lipid profile in obese patients, thereby reducing cardiovascular risks. The high prevalence of dyslipidemia and cardiovascular risk associated with obesity constitute a serious public health problem, a...
Flaviana Freitas Pedron, Glauco da Costa Alvarez, L. Patias et al.· ABCS Health Sciences· 0 citations
Dyslipidemia (DL), a common metabolic disorder,
negatively influences the regulation of glycemia, liver
function and insulin sensitivity and is a crucial factor
in the dramatic increase in metabolic diseases. In
India, the prevalence ranges from 15–20% in rural
populations to 25–30% indicating the wide-spread
prevalenc...
Naveen Kumar Billa, Darapuneni Radhika Chowdary, Sainath S. B. et al.· Research journal of biotechn...· 0 citations
Dyslipidemia, a major risk factor for cardiovascular diseases (CVDs), is characterized by abnormal lipid metabolism, typically presenting as elevated triglycerides, total cholesterol, low-density lipoprotein, and/or decreased high-density lipoprotein. In the Unani (Greco-Arabic) system of medicine, dyslipidemia is...
M. M. Ahmed, M. Khan, Syed Farhanda Farooq et al.· Hippocratic Journal of Unani...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.